Mylab Discovery Solutions, a leading healthcare diagnostics innovator, proudly introduced its first-ever Point-of-Care Device for Newborn Screening, MyNeoShield. This cutting-edge gadget has the potential to reshape neonatal healthcare by improving screening speed, accessibility, and affordability, ultimately contributing to life-saving interventions and the avoidance of life-long illnesses. All seven globally accepted newborn screening tests are supported.
Historically, newborn screening included complex steps, including sample collection, transfer to centralized labs, and a prolonged results waiting period, burdening remote areas. Costly equipment prevented smaller healthcare providers.
This innovative device revolutionizes newborn screening, offering:
- Rapid Results: Mylab’s technology provides results in 4 hours, compared to 24-72 hours traditionally, facilitating prompt intervention.
- Enhanced Accessibility: Smaller healthcare facilities can now offer screening, improving care accessibility, even in remote areas.
- Life-Saving Potential: Early detection through Mylab’s device prevents mental retardation, mortality, and lifelong illnesses, ensuring better newborn well-being.
Hasmukh Rawal, Co-founder & Managing Director of Mylab, expressed his enthusiasm for this development, saying, “At Mylab, we are deeply committed to advancing healthcare through innovation and accessibility. Our Point-of-Care Device for New-born Screening is a testament to that commitment. By making screening faster and more accessible, we aim to save lives and ensure that every child has the opportunity for a healthy and promising future.”
Scheduled for a November commercial launch, this Point-of-Care Newborn Screening Device will expand globally through strategic partnerships, targeting preventable conditions.
Tests covered:
- G-6-Phosphate Dehydrogenase Deficiency: Screens for an inherited condition causing severe anemia and jaundice.
- Galactosemia: Detects difficulties in metabolizing galactose, found in breast milk and formula.
- Phenylketonuria (PKU): Identifies a metabolic disorder leading to intellectual disabilities due to phenylalanine breakdown issues.
- Biotinidase Deficiency: Assesses the body’s ability to process essential B vitamin biotin.
- 17-Hydroxyprogesterone (17-OHP): Evaluates congenital adrenal hyperplasia, affecting adrenal hormones.
- Immunoreactive Trypsinogen (IRT): Screens for cystic fibrosis, a genetic lung and digestive condition.
- TSH: Tests for congenital hypothyroidism, assessing thyroid gland abnormalities.
